Personalized Medicine: DIANA – A Revolutionary Diagnostic Chamber

Brescia, 17 December 2024 – In a groundbreaking collaboration between Antares Vision Group, Isinnova, and the National Center for Gene Therapy and RNA-Based Drugs, the prototype of DIANA is scheduled to be completed by the end of June 2025.

DIANA (Diagnostica Intelligente per Analisi Non-invasiva Avanzata) represents a leap forward in personalized medicine by combining advanced non-invasive technologies with therapeutic monitoring, which enables more effective, patient-tailored medical treatments. DIANA can perform over 60 non-invasive tests in just 15 minutes and assesses key health indicators, including brain wave activity, cardiac function, blood composition, and more.

A significant step towards improving patient care, DIANA aims to accelerate and simplify diagnosis, monitor the effectiveness of therapies in real-time, and support the development of drugs personalized to each patient.

The diagnostic chamber conducts various tests, such as analyzing electrical brain activity, cardiac rhythms, blood composition, body composition, electrical muscle activity, and lung capacity. This comprehensive approach provides a detailed, personalized patient health profile, drastically reducing the time and cost associated with traditional diagnostic methods.

To put our technology into action, “we utilized both established and experimental technologies, integrating them into the design of DIANA,” explains Cristian Fracassi and Marco Silvestri of Isinnova, CEO and head of the DIANA project, respectively. “Our goal is not to replace doctors, but to streamline their work and accelerate the diagnostic process.”

Prof. Rosario Rizzuto, President of the National Center, adds, “By integrating DIANA with gene therapy protocols, we can monitor the real-time effectiveness of RNA-based therapies. This collaboration not only shortens research timelines but also simplifies diagnostics, enabling the development of more precise and sustainable treatments.”

Offering a new era for personalized medicine, “DIANA marks a paradigm shift in healthcare,” says Alberto Albertini, Innovation Center Director at Antares Vision Group. “By applying cutting-edge technology, we bridge scientific research with practical healthcare solutions. This project also highlights the power of collaboration between research institutions, companies, and universities to drive medical and technological progress.”

The DIANA prototype, DIANA-ATMP, will be ready by mid-2025 and used at the National Center for RNA & Gene Therapy to monitor patients undergoing advanced gene therapies. DIANA will play a crucial role in the data collection phase, accelerating the integration of high-quality information in real-time, even in remote healthcare settings.

This technology allows for seamless data integration from multiple sources, providing doctors with a comprehensive view of a patient’s health. By personalizing treatment plans based on individual characteristics, DIANA will enable more effective and targeted therapies while building valuable data archives for disease research.

Press review: